Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning
- Authors: Ceccherini-Silberstein F, Cento V, Cuypers L, Di Maio VC, Libin P, Lunar MM, Nevens F, Nowé A, Poljak M, Schrooten Y, Theys K, Van Laethem K, Vandamme AM
- Publication Year: 2017
- Journal: Infection Genetics and Evolution
- Link: https://www.sciencedirect.com/science/article/pii/S1567134817301582?via%3Dihub
Resistance-associated variants (RAVs) have been shown to influence treatment response to direct-acting antivirals (DAAs) and first generation NS3/4A protease inhibitors (PIs) in particular. Interpretation of hepatitis C virus (HCV) genotypic drug resistance remains a challenge, especially in patients who previously failed DAA therapy and need to be retreated with a second DAA based regimen. Bayesian […]
Read More